Daily or on demand oral TDF/FTC for HIV pre-exposure prophylaxis: experience from an hospital-based clinic in France.
暂无分享,去创建一个
C. Delaugerre | W. Rozenbaum | J. Molina | A. Brun | C. Pintado | M. Siguier | Marion Noret | S. Balavoine | B. Loze | Rebecca Bauer | A. Leplatois | A. Aslan | K. Moudachirou | M. Noret
[1] M. Boffito,et al. InterPrEP: internet‐based pre‐exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London – analysis of pharmacokinetics, safety and outcomes , 2018, HIV medicine.
[2] C. Delaugerre,et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. , 2017, The Lancet. Infectious diseases.
[3] A. Pozniak,et al. Rapidly declining HIV infection in MSM in central London. , 2017, The lancet. HIV.
[4] S. Goodreau,et al. Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] R. Grant,et al. Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users , 2017, AIDS.
[6] C. Delaugerre,et al. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial , 2017, The Journal of antimicrobial chemotherapy.
[7] C. Johnston,et al. Future prospects for new vaccines against sexually transmitted infections , 2016, Current opinion in infectious diseases.
[8] C. B. Hare,et al. Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation , 2016, Journal of acquired immune deficiency syndromes.
[9] D. Glidden,et al. Pharmacology supports on-demand PrEP. , 2016, The lancet. HIV.
[10] M. Hudgens,et al. A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. , 2016, The Journal of infectious diseases.
[11] W. Heneine,et al. Preexposure Prophylaxis Modality Preferences Among Men Who Have Sex With Men and Use Social Media in the United States , 2016, Journal of medical Internet research.
[12] Sheena McCormack,et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.
[13] E. Vittinghoff,et al. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. , 2016, JAMA internal medicine.
[14] David Thompson,et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. , 2015, The New England journal of medicine.
[15] E. Vittinghoff,et al. Sexual Frequency and Planning Among At-Risk Men Who Have Sex With Men in the United States: Implications for Event-Based Intermittent Pre-Exposure Prophylaxis , 2012, Journal of acquired immune deficiency syndromes.
[16] John T Brooks,et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.
[17] James D. Campbell,et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.
[18] David V Glidden,et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.
[19] W. Heneine,et al. Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection , 2010, Science Translational Medicine.
[20] L. Cuzin,et al. A large French prospective cohort of HIV‐infected patients: the Nadis Cohort , 2009, HIV medicine.
[21] Michael Monsour,et al. Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir , 2008, PLoS medicine.